司库奇尤单抗治疗中重度斑块状银屑病的临床应用价值
Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.
作者信息
Sekhon Sahil, Jeon Caleb, Nakamura Mio, Yan Di, Afifi Ladan, Bhutani Tina, Levin Ethan
机构信息
Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA.
出版信息
Psoriasis (Auckl). 2017 Nov 16;7:65-72. doi: 10.2147/PTT.S129792. eCollection 2017.
Abstract
Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic ixekizumab, approved for the treatment of moderate-severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab.
摘要
寻常型银屑病是一种慢性、免疫介导的全身性疾病，在美国影响着750万人。它可以通过多种疗法进行治疗，通常是联合使用，这些疗法包括局部用药、光疗、口服全身用药和生物制剂。生物制剂靶向参与银屑病发病机制的免疫系统特定成分，包括肿瘤坏死因子-α、白细胞介素-12、白细胞介素-17和白细胞介素-23。在美国被批准用于治疗中度至重度斑块状银屑病的生物制剂ixekizumab靶向白细胞介素-17。本综述描述了白细胞介素-17在银屑病中的作用、ixekizumab靶向这种细胞因子的机制以及ixekizumab的临床应用。
相似文献
1
Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis.司库奇尤单抗治疗中重度斑块状银屑病的临床应用价值
Psoriasis (Auckl). 2017 Nov 16;7:65-72. doi: 10.2147/PTT.S129792. eCollection 2017.
2
Emerging targeted therapies for plaque psoriasis - impact of ixekizumab.斑块状银屑病的新兴靶向疗法——司库奇尤单抗的影响
Clin Cosmet Investig Dermatol. 2017 Apr 21;10:133-139. doi: 10.2147/CCID.S111007. eCollection 2017.
4
Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.依奇珠单抗治疗中重度斑块状银屑病：NICE 单技术评估的循证评估组观点。
Pharmacoeconomics. 2018 Aug;36(8):917-927. doi: 10.1007/s40273-018-0629-2.
5
Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab.白细胞介素-17在斑块状银屑病中的作用：司库奇尤单抗的治疗潜力
Ther Clin Risk Manag. 2017 Mar 13;13:315-323. doi: 10.2147/TCRM.S111107. eCollection 2017.
6
Biologics for the primary care physician: Review and treatment of psoriasis.初级保健医生的生物制剂：银屑病的评估与治疗。
Dis Mon. 2019 Mar;65(3):51-90. doi: 10.1016/j.disamonth.2018.06.001. Epub 2018 Jul 20.
7
Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.司库奇尤单抗用于治疗中度至重度斑块状银屑病和银屑病关节炎的成人患者。
Expert Rev Clin Pharmacol. 2016 Nov;9(11):1423-1433. doi: 10.1080/17512433.2016.1242409. Epub 2016 Oct 11.
8
No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.无需改变药物类别：在银屑病中，司库奇尤单抗治疗后使用依奇珠单抗。
J Dermatolog Treat. 2019 May;30(3):216-220. doi: 10.1080/09546634.2018.1506081. Epub 2018 Sep 11.
9
Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.依奇珠单抗及其他美国食品药品监督管理局批准的生物制剂治疗中重度斑块型银屑病的额外应答者成本。
J Med Econ. 2017 Dec;20(12):1224-1230. doi: 10.1080/13696998.2017.1362413. Epub 2017 Aug 22.
10
Ixekizumab for the treatment of psoriasis: an update on new data since first approval.依奇珠单抗治疗银屑病：首次批准以来新数据的更新。
Expert Rev Clin Immunol. 2019 Feb;15(2):111-121. doi: 10.1080/1744666X.2019.1559730. Epub 2018 Dec 27.
引用本文的文献
1
A Systematic Review Evaluating the Effectiveness of Several Biological Therapies for the Treatment of Skin Psoriasis.一项评估几种生物疗法治疗皮肤银屑病有效性的系统评价。
Cureus. 2023 Dec 15;15(12):e50588. doi: 10.7759/cureus.50588. eCollection 2023 Dec.
2
Effect of interleukin-6, -17, -21, -22, and -23 and STAT3 on signal transduction pathways and their inhibition in autoimmune arthritis.白细胞介素-6、-17、-21、-22 和 -23 及 STAT3 对自身免疫性关节炎信号转导通路的影响及其抑制作用。
Immunol Res. 2021 Feb;69(1):26-42. doi: 10.1007/s12026-021-09173-9. Epub 2021 Jan 29.
3
T cell epitope mapping of secukinumab and ixekizumab in healthy donors.在健康供体中对司库奇尤单抗和依奇珠单抗的 T 细胞表位进行定位。
MAbs. 2020 Jan-Dec;12(1):1707418. doi: 10.1080/19420862.2019.1707418.
4
Transcription Factor Retinoid-Related Orphan Receptor γt: A Promising Target for the Treatment of Psoriasis.转录因子维 A 酸相关孤儿受体 γt：治疗银屑病的有前途的靶点。
Front Immunol. 2018 May 30;9:1210. doi: 10.3389/fimmu.2018.01210. eCollection 2018.
本文引用的文献
1
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy.司库奇尤单抗治疗中重度斑块状银屑病的聚焦：设计、研发及治疗应用
Drug Des Devel Ther. 2017 Jun 2;11:1643-1651. doi: 10.2147/DDDT.S92128. eCollection 2017.
2
Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.依奇珠单抗治疗对中重度银屑病患者皮肤相关人际关系困难的影响：两项 3 期临床试验的 12 周结果。
J Eur Acad Dermatol Venereol. 2017 Nov;31(11):1867-1875. doi: 10.1111/jdv.14377. Epub 2017 Sep 4.
3
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.比较依奇珠单抗和乌司奴单抗治疗中重度银屑病：IXORA-S 三期研究 24 周结果。
Br J Dermatol. 2017 Oct;177(4):1014-1023. doi: 10.1111/bjd.15666. Epub 2017 Jul 19.
4
The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.体重对依奇珠单抗疗效和安全性的影响：来自三项中度至重度斑块型银屑病患者随机、对照 3 期研究的综合数据库结果。
J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1196-1207. doi: 10.1111/jdv.14252. Epub 2017 May 4.
5
Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3).依奇珠单抗对比依那西普和安慰剂治疗中重度斑块状银屑病和非脓疱性掌跖银屑病患者的疗效：三项 3 期临床试验（UNCOVER-1、UNCOVER-2 和 UNCOVER-3）结果。
J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1686-1692. doi: 10.1111/jdv.14237. Epub 2017 Apr 26.
6
Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3.在随机 3 期临床试验中，依奇珠单抗治疗可迅速改善与健康相关的生活质量和瘙痒：UNCOVER-2 和 UNCOVER-3 的结果。
J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1483-1490. doi: 10.1111/jdv.14211. Epub 2017 Jun 28.
7
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.依奇珠单抗连续给药与间断治疗对比：两项银屑病3期试验的综合分析
J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1004-1013. doi: 10.1111/jdv.14163. Epub 2017 Mar 31.
8
Ixekizumab: A Review in Moderate to Severe Plaque Psoriasis.司库奇尤单抗：中重度斑块状银屑病的综述
Am J Clin Dermatol. 2017 Feb;18(1):147-158. doi: 10.1007/s40257-017-0254-4.
9
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.司库奇尤单抗治疗可改善中度至重度银屑病患者的指甲银屑病：UNCOVER-3随机、对照和开放标签阶段的结果
J Eur Acad Dermatol Venereol. 2017 Mar;31(3):477-482. doi: 10.1111/jdv.14033. Epub 2016 Dec 2.
10
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.在银屑病的 7 项临床试验中，来自 ixekizumab 的短期和长期安全性结果：依那西普比较和综合数据。
J Am Acad Dermatol. 2017 Mar;76(3):432-440.e17. doi: 10.1016/j.jaad.2016.09.026. Epub 2016 Nov 23.
Zotero 插件